ImmunityBio (NASDAQ:IBRX) Director Barry Simon Sells 165,000 Shares of Stock

ImmunityBio, Inc. (NASDAQ:IBRX) Director Barry Simon sold 165,000 shares of the company’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $10.25, for a total value of $1,691,250.00. Following the completion of the sale, the director owned 2,925,821 shares in the company, valued at approximately $29,989,665.25. This represents a 5.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

ImmunityBio Price Performance

ImmunityBio stock opened at $11.55 on Wednesday. The business has a 50 day simple moving average of $4.82 and a 200 day simple moving average of $3.24. The company has a market capitalization of $11.38 billion, a PE ratio of -30.39 and a beta of 0.14. ImmunityBio, Inc. has a one year low of $1.83 and a one year high of $12.28.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings data on Monday, March 2nd. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.02. The company had revenue of $38.29 million for the quarter. Equities analysts anticipate that ImmunityBio, Inc. will post -0.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on IBRX shares. Piper Sandler boosted their price target on shares of ImmunityBio from $5.00 to $7.00 and gave the company an “overweight” rating in a research report on Tuesday, January 20th. D. Boral Capital reiterated a “buy” rating and issued a $23.00 target price on shares of ImmunityBio in a research note on Monday. Jefferies Financial Group boosted their target price on ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Friday, December 12th. The Goldman Sachs Group restated a “buy” rating on shares of ImmunityBio in a research report on Monday. Finally, HC Wainwright lifted their price objective on ImmunityBio from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Monday. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $12.60.

Institutional Trading of ImmunityBio

Several hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC raised its position in ImmunityBio by 193.4% in the 1st quarter. AQR Capital Management LLC now owns 44,448 shares of the company’s stock worth $134,000 after purchasing an additional 29,297 shares during the last quarter. CWM LLC increased its stake in shares of ImmunityBio by 849.2% in the 2nd quarter. CWM LLC now owns 48,715 shares of the company’s stock valued at $129,000 after buying an additional 43,583 shares during the period. Dillon & Associates Inc. acquired a new stake in shares of ImmunityBio in the 2nd quarter valued at $68,000. Rathbones Group PLC raised its position in shares of ImmunityBio by 21.5% during the second quarter. Rathbones Group PLC now owns 117,420 shares of the company’s stock worth $310,000 after acquiring an additional 20,800 shares during the last quarter. Finally, Summit X LLC acquired a new position in shares of ImmunityBio during the second quarter valued at $28,000. 8.58% of the stock is owned by institutional investors.

Key Headlines Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Company reports ANKTIVA regulatory/approval expansion and broader global commercial reach, supporting larger addressable market and sales potential. ImmunityBio’s ANKTIVA Approvals Broaden Global Reach And Investor Opportunity
• Positive Sentiment: Management says ANKTIVA drove massive revenue growth—company reported ~700% year‑over‑year revenue increase and new global commercial partnerships covering multiple countries, signaling meaningful commercial traction. ImmunityBio, Inc.: ImmunityBio Reports 700% Year-Over-Year Revenue Growth…
• Positive Sentiment: Q4 results beat revenue and EPS loss expectations (reported loss $0.06 vs. consensus -$0.08; revenue ~$38.3M), which investors view as confirmation that commercial sales are scaling. ImmunityBio (IBRX) Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Market coverage and outlets highlight ANKTIVA-driven revenue surge and share gains toward a 52‑week high, reinforcing momentum and investor enthusiasm. ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth
• Positive Sentiment: An analyst shop (D. Boral Capital) reaffirmed a “buy” and set a $23 price target, providing an actionable upside thesis for price momentum. Benzinga
• Neutral Sentiment: Founder Dr. Patrick Soon‑Shiong will present at high‑profile cancer summits — visibility and credibility boost but not an immediate revenue driver. ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute…
• Neutral Sentiment: Chairman commentary and press pieces tease multi‑year ANKTIVA expansion and potential future indications; positive for sentiment but speculative for near‑term fundamentals. IBRX stock to open week on a high? Chairman teases Anktiva’s 3-year expansion plans…
• Negative Sentiment: Despite the revenue jump, the company remains unprofitable (negative EPS and a current-year analyst consensus loss), which keeps valuation and execution risk elevated for long‑term investors. ImmunityBio Q4 Press Release

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.